Faculty Profile: Rami Kantor, MD

Rami Kantor
Rami Kantor, MD
Associate Professor of Medicine
Medicine
Work: +1 401-793-4997
Rami Kantor's research focuses on the evolution of HIV drug resistance to antiretroviral medications, which jeopardizes treatment success. The research incorporates bioinformatics, sequence and phylogenetic analyses, databases and data management, as well as basic laboratory research. More specifically, he is studying the evolution of drug resistance in HIV variants that predominate in resource-limited settings and in developing countries, where the majority of the AIDS epidemic is located.

Biography

Rami Kantor is an internal medicine and infectious diseases physician, Associate Professor in the Division of Infectious Diseases. He came to Brown University in January 2005, after conducting post-doctoral HIV research fellowship at Stanford University. He completed his medical studies and internal medicine residency in Israel and his clinical infectious diseases training at Brown University/Lifespan. His main research interests are HIV diversity, molecular epidemiology and the evolution of drug resistance to antiretroviral drugs. The research incorporates bioinformatics, sequence and phylogenetic analyses, databases and data management, as well as basic laboratory research. Dr. Kantor is the author of more than 60 publications in the medical literature, as well as several book chapters. He is a reviewer of several journals including The Lancet and PLOS Medicine. He is involved in national and international collaborations, with focus on HIV/AIDS locally in RI and in resource-limited settings.

Institutions

MH

Research Description

Rami Kantor, an Associate Professor of Medicine, studies the evolution of HIV drug resistance to antiretroviral medications in patients who are taking those drugs, which jeopardizes treatment success. He investigates HIV diversity and its potential implications on the evolution of drug resistance. HIV researchers in the past 20 years focused on HIV-1 subtype B, the predominant variant in resource-rich setting such as North America, Europe, and Australia. However globally, non-B subtypes and recombinant forms predominate, and are responsible for >90% of HIV infection. The main research question is whether knowledge of drug resistance in subtype B can be implemented in non-subtype B infected persons. The research hypothesis is that the enormous diversity among HIV types, groups, subtypes, and recombinant forms has an impact on the evolution of drug resistance. Kantor's research incorporates bioinformatics, sequence and phylogenetic analyses, databases and data management, creation and improvement of various analysis tools, as well as basic laboratory research. He is focusing on the study of the evolution of drug resistance in HIV variants that predominate in resource-limited settings and in developing countries, where the majority of the AIDS epidemic is located.

Affiliations

International AIDS Society

Infectious Disease Society of America

HIV Medicne Association

American Academy of HIV Medicine

Selected Publications

  • 25. PA Chan, A Huang, R Kantor. Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: Implications for pre-exposure prophylaxis. Journal of the International AIDS Society 2012;15:17701. (2012)
  • 24. NE Alexander, PA Chan, T Rogo, Z Parillo, C Browning, B Isabell, C Calcione, S Chowdhury, P Simon, R Kantor. Interrupting Transmission of HIV and other Sexually Transmitted Infections in Rhode Island. Medicine and Health RI 2012;95:241-244. (2012)
  • 22. A Huang, J Hogan, S Istrail, A DeLong, D Katzenstein, R Kantor. Global Analysis of Sequence Diversity Within HIV-1 Subtypes Across Geographic Regions. Future Virology 2012;7:505-17 (2012)
  • 21. A DeLong, M Wu, J Wu, J Hogan, R Kantor. SQUAT (Sequence Quality Assessment Tool): A standalone computational tool for HIV sequence quality evaluation. AIDS Research and Human Retroviruses 2012;28:894-901. (2012)
  • 26. A Jiamsakul, R Kantor, PCK Li, S Sirivichayakul, T Sirisanthana, P Kantipong, CKC Lee, A Kamarulzaman, W Ratanasuwan, R Ditangco, T Singtoroj, S Sungkanuparph Comparison of Predicted Susceptibility between Genotype and Virtual Phenotype HIV Drug Resistance Interpretation Systems among Treatment-naive HIV-infected Patients in Asia: TASER-M Cohort Analysis. BMC Research Notes 2012;5:582. (2012)
  • 20. A Huang, R Kantor, A DeLong, L Schreier, S Istrail. QColors: An Algorithm for Conservative Viral Quasispecies Reconstruction from Short and Non-Contiguous Next Generation Sequencing Reads. Proceedings of Institute of Electrical and Electronics Engineers Conference on Bioinformatics and Biomedicine, Workshop on Computational Advances in Molecular Epidemiology; 2011;1:130-136. (2011)
  • 19. PA Chan, K Tashima, F Gillani, O Mintz, K Zeller, R Kantor. Transmitted Drug Resistance and Molecular Epidemiology in Antiretroviral Naïve HIV-1 Infected Patients Presenting to an Outpatient Clinic in Rhode Island. AIDS Research and Human Retroviruses 2011;7:275-81. (2011)
  • 18. Z El-Khatib, AK DeLong, D Katzenstein, AM Ekstrom, J Ledwaba, L Mohapi, F Laher, S Charalambous, A Karstaedt, M Petzold, L Morris, R Kantor. Viremia, drug resistance patterns and re-suppression among HIV-1 subtype C patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. Journal of AIDS and Clinical Research 2011;2:117. (2011)
  • 23. B Westley, AK Delong, CS Tray, D Sophearin, EM Dufort, E Nerrienet, L Schreier, JI Harwell, R Kantor. Prediction of Treatment Failure using 2010 WHO Guidelines is Associated with High Misclassification Rates and Drug Resistance among HIV-Infected Cambodian Children Clinical Infectious Diseases, 2012;55:432-440. (2010)
  • 17. R Kantor, L Diero, A DeLong, L Kamle, S Muyonga, F Mambo, W Emonyi, P Chan, EJ Carter, J Hogan, N Buziba. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clinical Infectious Diseases 2009;49:454-62 (2009)
  • 16. PA Chan, R Kantor. Transmitted Drug Resistance in Non-subtype B HIV-1 Infection. HIV Therapy 2009;3:447-465. (2009)
  • 15. R Kantor, J Gershoni. HIV/AIDS and the Genetic Revolution - Custom Tailoring Antiretroviral Regimens in the Management of HIV. The International Journal for Healthcare Technology and Management 2007;7:478-491. (2007)
  • 13. R Kantor. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Current Opinion in Infectious Diseases 2006;19:594-606. (2006)
  • 12. J Snoeck, R Kantor, RW Shafer, K Van Laethem, K Deforche, AP Carvalho, B Wynhoven, MA Soares, P Cane, J Clarke, C Pillay, S Sirivichayakul, K Ariyoshi, A Holguin, H Rudich, R Rodrigues, MB Bouzas, F Brun-Vézinet, C Reid, P Cahn, LF Brigido, Z Grossman, V Soriano, W Sugiura, P Phanuphak, L Morris, J Weber, D Pillay, A Tanuri, RP Harrigan, R Camacho, JM Schapiro, D Katzenstein and AM Vandamme. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of the Human Immunodeficiency Virus are subtype dependent. Antimicrobial Agents and Chemotherapy, 2006; 50:694-701. (2006)
  • 14. SY Rhee, R Kantor, D Katzenstein, R Camacho, L Morris, D Pillay, Z Grossman, P Phanuphak, P Cahn, V Soriano, LF Brigido, AM Vandamme, A Tanuri, J Weber, W Sugiura, JM Schapiro and RW Shafer. HIV-1 Pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS 2006;20:643-51. (2006)
  • 11. EJ Lee, R Kantor, L Zijenah, W Sheldon, P Mateta, E Johnston, J Wells, A Shetty, H Coovadia, Y Maldonado, SA Jones, C Contag, M Bassett, D Katzenstein. Breast-milk shedding of drug resistant subtype C HIV-1 among women receiving single dose nevirapine. Journal of Infectious Diseases 2005; 192:1260-4. (2005)
  • 10. R Kantor, D Katzenstein, B Efron, AP Carvalho, B Wynhoven, M Soares, P Cane, J Clarke, J Snoeck, C Pillay, S Sirivichayakul, K Ariyoshi, A Holguin, P Weidle, H Rudich, R Rodrigues, MB Bouzas, P Cahn, L Brigido, Z Grossman, V Soriano, W Sugiura, P Phanuphak, L Morris, AM Vandamme, J Weber, D Pillay, A Tanuri, R Harrigan, R Camacho, J Schapiro RW Shafer. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotypic evolution: results of a global collaboration. PLOS Medicine 2005; 2:e112. (2005)
  • 9. R Kantor, D Katzenstein. Drug resistance in non-subtype B HIV-1. Journal of Clinical Virology 2004;29:152-9. (2004)
  • 8. R Kantor, RW Shafer, S Follansbee, J Taylor, D Shilane, L Hurley, DP Nguyen, D Katzenstein, WJ Fessel. Evolution of drug resistance in HIV-1 among persons failing antiretroviral therapy. AIDS 2004;18:1503-11. (2004)
  • 7. R Kantor, M Bakhanashvili, A Achiron. The Clinical and prognostic implications of a mutant CCR5 gene in multiple sclerosis patients. Neurology 2003; 61: 238-240. (2003)
  • 6. R Kantor, D Katzenstein. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Reviews 2003; 5: 25-35. (2003)
  • 5. M Gonzales, TD Wu, J Taylor, I Belitskaya, R Kantor, D Israelski, S Chou, A Zolopa, WJ Fessel, RW Shafer. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17: 791-9. (2003)
  • 4. R Kantor, L Zijenah, RW Shafer, S Mutetwa, E Johnston, R Lloyd, A von Lieven, D Israelski D Katzenstein. HIV-1 subtype C reverse transcriptase and protease genotypes in patients from Zimbabwe failing antiretroviral therapy. AIDS Research and Human Retroviruses 2002; 18: 1407-13. (2002)
  • 3. R Kantor, JW Fessel, A Zolopa, D Israelski, N Shulman, J Montoya, M Harbour, J Schapiro, RW Shafer. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrobial Agents and Chemotherapy 2002; 46:1086-92. (2002)
  • 2. R Kantor, R Machakeno, M Gonzales, K Dupnik, J Schapiro, R W Shafer. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: An Expanded Data Model Integrating Natural Language Text and Sequence Analysis. Nucleic Acids Research 2001; 29: 296-299. (2001)
  • 1. RW Shafer, R Kantor, M Gonzales. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Reviews 2000; 2: 211-228. (2000)